DAX24.351 +0,1%Est505.752 +0,1%MSCI World4.343 -0,1%Top 10 Crypto11,28 +1,9%Nas23.474 -0,5%Bitcoin74.051 -0,7%Euro1,1776 ±0,0%Öl61,70 +1,5%Gold4.332 -4,4%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 NVIDIA 918422 DroneShield A2DMAA Novo Nordisk A3EU6F Deutsche Telekom 555750 BYD A0M4W9 Bayer BAY001 Nike 866993 Lufthansa 823212 Siemens Energy ENER6Y BASF BASF11 Tesla A1CX3T Allianz 840400 Mercedes-Benz Group (ex Daimler) 710000 RENK RENK73
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX beendet Handel stabil -- Wall Street letztlich im Minus -- Aktien von Rheinmetall, HENSOLDT, RENK & TKMS von Selenskyj/Trump-Treffen belastet -- NVIDIA, EOS, Tesla, Realty Income im Fokus
Top News
Allianz Global Investors Ausblick 2026: Wo sich für Anleihenanleger Chancen bieten Allianz Global Investors Ausblick 2026: Wo sich für Anleihenanleger Chancen bieten
Hot Stocks heute: Looser-Aktien 2025 kaufen - Trade der Woche: Tesla Short Hot Stocks heute: Looser-Aktien 2025 kaufen - Trade der Woche: Tesla Short
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

PTC Therapeutics Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
66,00 EUR ±0,00 EUR ±0,00 %
BMN
77,63 USD -0,91 USD -1,16 %
BTT
PTC Therapeutics jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.5,36 Mrd. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA1W0MW

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS69366J2006

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolPTCT

PTC Therapeutics Aktien News

DatumMeistgelesen
PR NewswirePTC Therapeutics Announces Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) in Japan
PR NewswirePTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswirePTC Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Wer­bungPTC Therapeutics-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswirePTC Therapeutics Announces Health Canada Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU)
MotleyFoolPTC Therapeutics Swings to a Profit on $211 Million in Revenue — Is This Why a Major Fund Just Invested $32 Million?
PR NewswirePTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MotleyFoolA PTC Therapeutics (PTCT) Insider Sold 10,000 Shares for $795,000
PR NewswireSandisk Set to Join S&P 500; Upwork, First Interstate BancSystem, PTC Therapeutics to Join S&P SmallCap 600
PR NewswirePTC Therapeutics to Host R&D Day
MotleyFoolThis Fund Sold $30 Million in PTC Therapeutics Shares Amid a 93% Rally: Here’s Why
ZacksCompared to Estimates, PTC Therapeutics (PTCT) Q3 Earnings: A Look at Key Metrics
ZacksPTC Therapeutics (PTCT) Q3 Earnings and Revenues Top Estimates
PR NewswirePTC Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
PR NewswirePTC Therapeutics to Participate at Upcoming Investor Conferences
ZacksPTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
PR NewswirePTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswirePTC Therapeutics to Host Conference Call to Discuss Third Quarter 2025 Financial Results
PR NewswirePTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BenzingaPTC Therapeutics Could Challenge BioMarin For Metabolic Disorder Treatment
MotleyFoolHere's Why Shares in PTC Therapeutics Soared This Week
BenzingaPTC Therapeutics Stock Is Stuck In A Multi-Year Slump
PR NewswirePTC Therapeutics to Participate at Upcoming Investor Conferences
BenzingaPTC Therapeutics Faces FDA Rejection On Rare Disease Treatment Over Efficacy Concerns
PR NewswirePTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA
ZacksPTC Therapeutics (PTCT) Reports Q2 Earnings: What Key Metrics Have to Say
ZacksPTC Therapeutics (PTCT) Reports Q2 Loss, Beats Revenue Estimates
PR NewswirePTC Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
BenzingaPTC Therapeutics Earnings Preview
ZacksPTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
ZacksPTC Therapeutics (PTCT) Surges 11.2%: Is This an Indication of Further Gains?
BenzingaSephience Gets FDA Approval, Now A Key Revenue Driver For PTC Therapeutics
BenzingaThese Analysts Increase Their Forecasts On PTC Therapeutics
PR NewswirePTC Therapeutics Announces FDA Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU)
PR NewswirePTC Therapeutics to Host Conference Call to Discuss Second Quarter 2025 Financial Results
PR NewswireSephience™ (sepiapterin) Granted Marketing Authorization by the European Commission for the Treatment of Children and Adults Living with Phenylketonuria (PKU)
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
PR NewswirePTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

PTC Therapeutics News

PTC Therapeutics News: auf dieser Seite finden Sie alle PTC Therapeutics News und Nachrichten zur PTC Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch PTC Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um PTC Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.